EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Resected EGFR -mutated non-small-cell lung cancers: incidence and outcomes in a European population (GFPC Exerpos Study)

Jean-Bernard Auliac iD, Pascal-Alexandre Thomas, Olivier Bylicki, Florian Guisier iD, Hubert Curcio, AlainVegnenègre, Aurelie Swalduz, Marie Wislez, Jacques Le Treut, Chantal Decroisette, Victor Basse, Lionel Falchero und 7 weitere

Therapeutic Advances in Medical Oncology · 2024-01 · 16

DOI: 10.1177/17588359241236451 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Therapeutic Advances in Medical Oncology, online erschienen am 06.03.2024. Verfasst von Jean-Bernard Auliac und 18 weiteren Autor:innen. Beteiligte Einrichtung: Service de Pneumologie, Pneumology Department, CHI Créteil, 40 Avenue de Verdun, Creteil 94010, France. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: astra zeneca.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Few epidemiological data are available on surgically treated Caucasian patients with non-small-cell lung cancers (NSCLCs) harboring epidermal growth factor receptor ( EGFR) mutations. The main objective of this study was to describe, in the real-world setting, these patients’ incidence, clinical, and tumoral characteristics.

Methods

The participating centers included all consecutive localized non-squamous NSCLC patients undergoing surgery between January 2018 and December 2019 in France. EGFR status was determined retrospectively when not available before surgery.

Results

The study includes 1391 no squamous NSCLC patients from 16 centers; EGFR status was determined before surgery in 692 (49.7%) of the cases and conducted as part of the study for 699 (50.3%); 171 (12.3%) were EGFR mutated; median age: 70 (range: 36–88) years; female: 59.6%; never smokers: 75.7%; non-squamous histology 97.7%, programmed death ligand-1 expression 0%/1–49%/⩾50 in 60.5%/25.7%/13.8%, respectively. Surgery was predominantly lobectomy (81%) or segmentectomy (14.9%), with systematic lymph node dissection in 95.9%. Resection completeness was R0 for 97%. Post-surgery staging was as follows: IA: 52%, IB: 16%, IIA: 4%, IIB: 10%, IIIA: 16%, and IIIB: 0.05%; EGFR mutation exon was Del19/exon 21 ( L858R)/20/18 in 37.4%/36.8%/14%, and 6.4% of cases, respectively; 31 (18%) patients received adjuvant treatment (chemotherapy: 93%, EGFR tyrosine kinase inhibitor: 0%, radiotherapy: 20%). After a median follow-up of 31 (95% confidence interval: 29.6–33.1) months, 45 (26%) patients relapsed: 11/45 (24%) locally and 34 (76%) with metastatic progression. Median disease-free survival (DFS) and overall survival were not reached and 3-year DFS was 60%.

Conclusion

This real-world analysis provides the incidence and outcomes of resected EGFR-mutated NSCLCs in a European patient cohort.

Schlagwörter

Stichwörter der Autor:innen

EGFR mutationlung cancer managementsurgery

Autor:innen und Institutionen

  • Service de Pneumologie, Pneumology Department, CHI Créteil, 40 Avenue de Verdun, Creteil 94010, France.
  • Thoracic Surgery Department, Assistance Publique Hopitaux de Marseille, Marseille, France.
  • Pneumology Department, Hôpital d'instruction des Armées Sainte-Anne, Toulon, France.
  • Service de Pneumologie, Oncologie Thoracique et Soins Intensifs Respiratoires, CHU Rouen, Rouen, France.
  • Oncology Department, Centre Francois Baclesse, Caen, France.
  • Pneumology Department, CHU Limoges - Hopital Dupuytren, Limoges, France.

ORCID-Profile: Jean-Bernard Auliac, Florian Guisier, Christos Chouaïd

Förderung

  • astra zeneca

Zitieren

APA

Auliac, J. B., Thomas, P. A., Bylicki, O., Guisier, F., Curcio, H., AlainVegnenègre, Swalduz, A., Wislez, M., Le Treut, J., Decroisette, C., Basse, V., Falchero, L., De Chabot, G., Moreau, D., Huchot, E., Lupo Mansuet, A., Blons, H., Chouaïd, C., & Greillier, L. (2024). Resected EGFR -mutated non-small-cell lung cancers: incidence and outcomes in a European population (GFPC Exerpos Study). Therapeutic Advances in Medical Oncology, 16. https://doi.org/10.1177/17588359241236451

Vancouver

Auliac JB, Thomas PA, Bylicki O, Guisier F, Curcio H, AlainVegnenègre, et al. Resected EGFR -mutated non-small-cell lung cancers: incidence and outcomes in a European population (GFPC Exerpos Study). Therapeutic Advances in Medical Oncology. 2024;16. doi:10.1177/17588359241236451

BibTeX
@article{Auliac2024,
  author = {Auliac, Jean-Bernard and Thomas, Pascal-Alexandre and Bylicki, Olivier and Guisier, Florian and Curcio, Hubert and AlainVegnenègre and Swalduz, Aurelie and Wislez, Marie and Le Treut, Jacques and Decroisette, Chantal and Basse, Victor and Falchero, Lionel and De Chabot, Gonzague and Moreau, Diane and Huchot, Eric and Lupo Mansuet, Audrey and Blons, Helene and Chouaïd, Christos and Greillier, Laurent},
  title = {Resected EGFR -mutated non-small-cell lung cancers: incidence and outcomes in a European population (GFPC Exerpos Study)},
  journal = {Therapeutic Advances in Medical Oncology},
  year = {2024},
  volume = {16},
  doi = {10.1177/17588359241236451}
}
Kostenlos starten →